Selecting the appropriate screening method and interval for the early detection of hepatitis C virus (HCV) infection in low-resourced haemodialysis settings is a challenge. The challenge occurs when patients are classified as HCV-RNA positive but negative to HCV-core antigen (HCV-coreAg), anti-HCV and genotyping tests. We aim to clarify the inconsistency between HCV-RNA, HCV-coreAg, anti-HCV and HCV genotyping tests in haemodialysis patients and determine the reliability of HCV-coreAg as a routine two-monthly screening strategy. Haemodialysis patients were tested every 2 months between 2012 and 2014 at the largest district haemodialysis unit in Ho Chi Minh City, Vietnam, for aminotransferases, anti-HCV antibodies, HCV-coreAg, HCV-RNA and HCV genotype. HCV-coreAg and anti-HCV results were tested against HCV-RNA for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV). All 201 patients participated in the study. The HCVcoreAg test performed better than the anti-HCV test for sensitivity (100% vs 31%), NPV (100% vs 90%) and accuracy (100% vs 90%). The HCV-coreAg and anti-HCV tests performed no differently for specificity (100% and 98%, respectively) or PPV (100% and 73%, respectively). Kappa values for HCV-coreAg and anti-HCV tests were 1 and 0.39, respectively. Early detection of HCV for the purpose of infection prevention requires a high level of sensitivity and HCV-coreAg performed better in our chronic haemodialysis population as a two-monthly screening method than routine anti-HCV testing. HCV-coreAg test is less labour-intensive with a higher level of accuracy in patients with low viral loads making it cost effective for low-resourced settings. Repeating genotyping may be required in HCV-coreAg positive patients with a low viral load.
| Data collection and laboratory tests
Current and new patients were tested for HCV every 2 months and their patient records were used to collect information on age and sex, duration and frequency of haemodialysis treatment. Trained staffs collected blood samples prior to each patient's scheduled haemodialysis treatment. The same qualified laboratory technician who was blinded to sample source tested all samples at an ISO 15189:2012 accredited medical and research laboratory. 19 Because the minimum window period for a positive anti-HCV test is 1-1.5 months postinfection 3, 11, 12 we used a two-monthly screening interval to test anti-HCV against tests including HCV-coreAg, HCV-RNA and HCV genotyping tests that are recognised as effective in identifying HCV early. 16, 20, 21 Laboratory tests included aspartate aminotransferase (AST) and in-house quantitative HCV PCR assays. The detection limit of HCV-coreAg assay corresponded to 600-1000 IU/mL of HCV-RNA. 16 An in-house quantitative HCV PCR was developed for research purpose and validated 20 with the lower limit of detection was 93 IU/mL of HCV-RNA. The quality of all these assays is described in detail elsewhere. 9, 13, 20 All PCR positive results were tested for HCV genotype by TRUGENE HCV 5′NC Genotyping kit (SIEMENS) that had a lower limit of detection of 5000 IU/mL of HCV-RNA. 21 
| RE SULTS

| Demographics, treatment and clinical characteristics
All 201 patients undergoing haemodialysis between 2012 and 2014 and were successfully enrolled of whom 48% were male and the mean age was 57 years (SD ± 16 years) ( Table 1 ). The mean time spent on haemodialysis was 14 months (SD ± 8 months) and the mean number of haemodialysis treatment was 154 (SD ± 104 events). Levels for AST, ALT and GGT were lower than 40 IU/L and were not different between patients with and without HCV (data not shown).
| Principal features of HCV PCR positive patients and comparison between HCV-coreAg, anti-HCV and HCV PCR tests
The rate of HCV-RNA detection was 26/201 and all 26 were HCVcoreAg positive. In contrast, none of HCV-coreAg negative patients tested positive for HCV-RNA (Table 2) . Eight (31%, 8/26) HCV PCR positive patients could not be genotyped due to a low viral load which is below the test's lower limit of detection of 5000 IU/mL of HCV-RNA. Of the remaining 18 typable HCV PCR positive patients the viral genotype distribution was 1b (8 patients), 1a (5 patients) and 6a (5 patients) (data not shown).
The anti-HCV-negative rate was 190/201 of whom 10% (18/190) were HCV-RNA positive (Table 2) . Of the 11/201 patients who tested anti-HCV-positive, 27% (3/11) were HCV PCR negative. The sensitivity of HCV-coreAg was 100% (95% CI 87%-100%) and was higher than anti-HCV test (31%, 95% CI 14%-52%) (Appendices 1 and 2). The specificity of HCV-coreAg (100%, 95% CI 98%-100%) was similar to anti-HCV test (98%, 95% CI 95%-100%). The PPV of HCV-coreAg (100%, 95% CI 87%-100%) was not different to that of anti-HCV test (73%, 95% CI 43%-90%). The NPV of HCV-coreAg (100%, 95% CI 98%-100%) was higher than that of anti-HCV test (90%, 95% CI 88%-92%). The accuracy of HCV-coreAg test (100%, 95% CI 98%-100%) was higher than that of anti-HCV test (90%, 95%
CI 85%-93%). The agreement between HCV-RNA and HCV-coreAg tests was perfect (k = 1.0) but poor between HCV-RNA and anti-HCV tests (k = 0.39).
| D ISCUSS I ON
Hepatitis C virus infection remains a burden and a risk of chronic haemodialysis populations, 4 including our patient population, 9 and significantly increases the risk of death. [23] [24] [25] [26] [27] Diagnosing HCV infections in its acute phase is pivotal for providing prompt antiviral treatment to minimise the impact of the infection. 28 Early detection of HCV infection is also pivotal for the prevention of further spread of infection in vulnerable haemodialysis patients who experience multiple invasive procedures.
7,29
Biochemical markers for HCV infection in chronic haemodialysis population are not equally accurate in identifying early HCV infection. We identified in our 201 haemodialysis patients that, in 14, 31 We also demonstrated that a twomonthly screening interval using HCV-coreAg test detected early HCV infection even when genotyping under-performs due to low viral loads. Repeating genotyping test for HCV-coreAg positive patients will prevent falsely untypable results. The kappa statistic in our sample illustrated the HCV-coreAg test has a higher level of reliability compared with the anti-HCV test. We understand that the kappa value of anti-HCV test may have increased with a longer interval between screenings and may be responsible for the current interval of 6-12 months using anti-HCV testing.
TA B L E 2 Comparability of HCV-coreAg and anti-HCV with HCV-RNA test results
Screening tests
HCV-RNA
5 Anti-HCV test is useful for ruling out HCV infection in low-prevalence settings. 
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